Voydeya has been approved as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of ..read more

In the beginning of March, Sahlgrenska Science Park, GoCo Health Innovation City, AstraZeneca, and other members of Health Innovation West invited participants, students, researchers, tech enthusiasts, life science experts, entrepreneurs, and others to a femtech innovation hackathon, a hackaton focused on reducing the gender health gap and advancing women’s health. Initiators of the hackaton were ..read more

The two companies have entered into an agreement regarding BAN2802, a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer’s disease. “I ..read more

Boston’s Kendall Square, close to Massachusetts Institute of Technology (MIT), is known as “The most innovative square mile on the planet” and, apart from our preference for the metric system, there just might be something we could learn from the Americans. One of the recommendations is that public and private stakeholders, inspired by the success ..read more

Ultimovacs has announced a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several cancer indications and immunotherapy combinations, and we are prepared for both challenges and accomplishments along the way. We anticipate ..read more

Sound Bioventures participated in the financing round, which raised a total of USD 24.5 million, and joins an existing investor syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford. In conjunction with this financing, Thomas Tan, Principal at Sound Bioventures, will join Theolytics’ Board of Directors. Read more ..read more

Personalized medicine, weight loss remedies and new treatments for widespread ailments are among the rising areas of high interest in the biotechnology and therapeutic arenas, according to executive chairman of Flerie Invest, Thomas Eldered. Thomas Eldered talked with Nordic Life Science about the Nordic and global life science financial landscapes and Flerie’s role in funding ..read more

Mölnlycke Health Care has signed an agreement to acquire P.G.F. Industry Solutions, the Austrian manufacturer of Granudacyn, a range of solutions for wound cleansing and moisturizing. Mölnlycke and P.G.F. have worked together for five years on the manufacturing and distribution of Granudacyn, a range of solution and gel products intended for use in the cleansing ..read more

Curida Holding has announced a significant growth investment from Signet Healthcare Partners, a New York-based healthcare private equity firm together with existing shareholders, Canica, Investinor, Klaveness Marine and Farvatn Private Equity. This investment will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position, it states. The total investment ..read more

At the Ordinary General Meeting Thursday 11th of April three new life science profiles were elected to Medicon Valley Alliance's (MVA's) Board of Directors. The new board members are Maria Björkqvist, Dean, Faculty of Medicine, Lund University, Professor, Research group leader Brain Disease biomarker Unit, Julia Davies, Professor of Oral Biology at Malmö University, Professor ..read more